Cardiopoietic Stem Cell Therapy in Heart Failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) Multicenter Randomized Trial With Lineage-Specified Biologics.

Jozef Bartunek,Atta Behfar,Dariouch Dolatabadi,Marc Vanderheyden,Miodrag Ostojic,Jo Dens,Badih El Nakadi,Marko Banovic,Branko Beleslin,Mathias Vrolix,Victor Legrand,C. Vrints,Jean-Louis Vanoverschelde,Ruben Crespo-Diaz,Christian Homsy,Michal Tendera,Scott A. Waldman,William Wijns,Andre Terzic

Cardiopoietic Stem Cell Therapy in Heart Failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) Multicenter Randomized Trial With Lineage-Specified Biologics.

2013

Jozef Bartunek
Atta Behfar
Dariouch Dolatabadi
Marc Vanderheyden
Miodrag Ostojic
Jo Dens
Badih El Nakadi
Marko Banovic
Branko Beleslin
Mathias Vrolix
Victor Legrand
C. Vrints
Jean-Louis Vanoverschelde
Ruben Crespo-Diaz
Christian Homsy
Michal Tendera
Scott A. Waldman
William Wijns
Andre Terzic

The C-CURE trial implements the paradigm of lineage guidance in cell therapy. Cardiopoietic stem cell therapy was found feasible and safe with signs of benefit in chronic heart failure, meriting definitive clinical evaluation. (C-Cure Clinical Trial; NCT00810238).

Keywords:

Clinical trial
Stem-cell therapy
Heart failure
Stem cell
Hematopoietic stem cell transplantation
Randomized controlled trial
Cardiology
Cell therapy
Ischemic cardiomyopathy
Internal medicine
Medicine
Ejection fraction

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

399

Citations